



FOR IMMEDIATE RELEASE

November 1, 2004, Lenexa, KS- VasoGenix Pharmaceuticals, Inc. completes Series B preferred stock offering and raised just over \$1 million. Dr. Lee Southard, President and Chairman, said "I am pleased to announce that VasoGenix Pharmaceuticals, Inc. has completed the Series B preferred stock offering and raised just over \$1 million. The offering was slightly over subscribed. The company extends its gratitude to all who participated in the offering. Together with the Series A offering the company has raised \$1.755 million. Funding has allowed us to make progress in the critical development steps along the preclinical path toward filing of the IND with the FDA and commencement of clinical trials. Our intellectual property position was also strengthened in the cardiology areas of application for the product under development."

VasoGenix Pharmaceuticals is a biopharmaceutical company developing CGRP as an emergency room treatment for heart attack. Heart attack is America's # 1 killer.